# First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-cemiplimab-monotherapy-and-continued-cemiplimab-beyond-progression/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Mustafa Özgüroğlu,Saadettin Kılıçkap,Ahmet Sezer,Mahmut Gümüş,Igor Bondarenko,Miranda Gogishvili,Marina Nechaeva,Michael Schenker,İrfan Çiçin,Gwo Fuang Ho,Yaroslav Kulyaba,Kasimova Zyuhal,Roxana-Ioana Scheusan,Marina Chiara Garassino,Xuanyao He,Manika Kaul,Emmanuel Chiebuka Okoye,Yuntong Li,Siyu Li,Jean‐François Pouliot,Frank Seebach,Israel Lowy,Giuseppe Gullo,Petra Rietschel |
| Citations | 102 |
| DOI | 10.1016/s1470-2045(23)00329-7 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4385803968 |
| PMID | 37591293 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Gwo Fuang Ho](https://scholariq.org/researchers/gwo-fuang-ho/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.